印度尼西亚的癌症治疗费用是由印度尼西亚病例基础群组（INA-CBGs）根据称为INA-CBG价格的代码确定的。然而，公正的索赔应基于疾病的严重程度和医院治疗的等级，而不是代号价格。事实上，癌症治疗的真实成本受到多种因素的影响，包括阶段、合并症和严重程度（INA-CBG编码、医院类型、医院等级、治疗等级、副作用和住院时间），因此，在许多情况下，实际成本和收取给患者的INA-CBG价格之间存在差异。本研究旨在调查在印度尼西亚的一家肿瘤中心医院中，肺癌、宫颈癌和乳腺癌等病例的真实治疗费用与INA-CBG的价格之间的差异。这项工作使用了一项观察性研究，并从医院财务数据和患者病历中回顾性地获取数据。然后使用单样本t检验分析数据，以确定实际成本和INA-CBG成本之间的差异。结果表明，在二期肺癌治疗中，2级C-4-13-II代码的成本和3级C-4-13-II代码和3级C-4-13-III的成本与INA-CBG的成本没有显着差异，sig值分别为0.683、0.151和0.650，其中显着性水平（t alpha）超过0.05。此外，具有C-4-13-I和C-4-13-II代码的宫颈癌治疗成本在1级和2级中分别呈现出0.155和0.720的sig值。最后，C-4-12-II代码3级的乳腺癌患者治疗成本sig值为0.145，C-4-13-II代码3级的患者治疗成本sig值为0.091。虽然统计评估表明有些情况存在显着差异，而其他情况则没有，但在实际情况下，INA-CBG和实际成本之间存在差异，政府和利益相关者必须评估这种差异，以为癌症患者提供公正。版权所有：© Pharmacy Practice。

In Indonesia, the cost of cancer treatment has been determined by the Indonesian Case Base Groups (INA-CBGs) based on a code called the INA-CBG's rates. However, a fair claim should be based on the severity of the disease and the class of treatment in the hospital, not on the rates of code. In fact, the real cost of therapy for cancer is influenced by several factors including stage, comorbidity, and severity (INA-CBGs coding, type of hospital, hospital class, treatment grade, side effects, and length of stay), so in many cases, there are reported differences between the real costs and the INA-CBGs rates charged to patients.This study aims to investigate the difference between real treatment costs and INA-CBG's rates for cases of lung cancer, cervical cancer, and breast cancer at a cancer center hospital in Indonesia.This work uses an observational study, and the data were taken retrospectively from hospital financial data and patient medical records. The data were then analyzed using a one-sample t-test to determine the difference between real costs and INA-CBGs costs.The results showed that there was no significant difference between real costs and INA-CBG's cost on stage II lung cancer treatment in grade 2 with a sig. value of 0.683; code C-4-13-II in grade 3 with a sig. value of 0.151; and code C-4-13-III in grade 3 with a sig. value of 0.650; where the significance level (t alpha) is more than 0.05. Furthermore, the treatment costs for cervical cancer with codes C-4-13-I and C-4-13-II in grade 1 had sig. values of 0.155 and 0.720 respectively. Lastly, the treatment cost for breast cancer patients with codes C-4-12-II in grade 3 had a sig. value of 0.145 and code C-4-13-II in grade 3 showed a sig. value of 0.091.Although statistical evaluation showed a significant difference for some cases and not significant for other cases, in real conditions, there is a difference between the INA-CBGs and the real costs that must be evaluated by the government and stakeholders to provide justice for cancer patients.Copyright: © Pharmacy Practice.